Conference Correspondent

Conference Correspondent

Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.

PREAMBLE (Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation) is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with one line of prior therapy.

Novel triplet combinations are being evaluated in both the newly diagnosed and relapsed/refractory settings in multiple myeloma. This study evaluates the efficacy and safety of ixazomib, pomalidomide, and dexamethasone combination therapy in a heavily pretreated, high-risk patient population.

Payers seek to understand the value of myeloma treatment options by assessing outcomes relative to cost. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.

As more patients receive maintenance therapy for multiple myeloma, researchers seek to evaluate the impact of toxicities associated with long-term treatment on health-related quality of life in these patient populations.

Recent data showed that lenalidomide maintenance therapy is an effective option for both transplant-eligible and nontransplant-eligible patients with multiple myeloma.

The majority of patients with smoldering multiple myeloma do not receive active treatment. In this study, treatment of a high-risk population with lenalidomide and dexamethasone yielded favorable patient outcomes.

Investigational agents with novel mechanisms of action continue to show promise in treating multiple myeloma. In this study, researchers report findings of a phase 1a/1b study evaluating an oral HDAC6 inhibitor.

Healthcare stakeholders have formulated a number of management approaches to ensure that patients receive appropriate therapies. Here, clinicians at Cleveland Clinic report on a response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.

This phase 2 study of elotuzumab, lenalidomide, and dexamethasone combination therapy in a high-risk population of patients with smoldering multiple myeloma showed promising efficacy and tolerability.

Page 13 of 19
Results 121 - 130 of 190
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME